Method of treating clinical mastitis
SUBSTANCE: invention relates to medicine, namely to veterinary and veterinary obstetrics, and can be applied for the treatment of clinical mastitis in cows. For this purpose after evening milking for 4 days, parts of the udder with signs of mastitis are influenced with an alternating magnetic field from the magnetic-therapeutic apparatus AMnp-02 "Solnyshko". The duration of exposure constitutes 10 minutes. Mastoxidine, heated to 40°C, in a dose of 20 ml three days successively, is additionally intracisternally introduced for 3 days running.
EFFECT: method ensures an increase of the treatment efficiency due to the enforcement of mastoxidine action at deep cellular and intra-cellular levels with the acceleration of its penetration in tissues.
1 dwg, 2 tbl, 2 ex
The invention relates to the field of veterinary medicine, veterinary obstetrics and can be used for treatment of clinical mastitis cows with application of a magnetic field.
A method of treating patients with chronic catarrhal mastitis cows with ultrasound. The method includes the scoring of the affected lobe intensity ultrasound 0.9 W/cm2, a frequency of 880 kHz, exposure, 10 minutes and intracisternally introduction of deferol And at a dose of 10.0 ml for 3 consecutive days. Method has an analgesic effect, promotes the resorption of infiltrates, stimulates the factors of nonspecific resistance (VI Slobodyanik, VA Wigs. The use of ultrasound in chronic mastitis in cows. - M., 1988. - P. 12-14).
A disadvantage of this method of treatment efficiency is low, it is 35%-60%.
A method of treatment comprising ultraviolet irradiation with a stationary mercury-quartz lamp "Solux". The udder is irradiated twice a day for 30-60 minutes. The distance from the lamp to the udder 60-80 see the Intensity of the light flux is determined by thermal sensation of the hands placed on the irradiated portion of the surface of the animal's body (I. G. Konoplev, V. N. The shulyat'ev. Inflammation of the udder in cows. A training manual. Kirov, St. Petersburg. - 2010. Pp. 230-233).
The disadvantage of this method - PR�short period of treatment and low therapeutic efficacy.
A method of treatment using nishinasuno LTK laser radiation "Zorka". It is used topically on the affected share mode No. 2 in the morning and evening after milking, exposure for 2 minutes. The principle of action was to stimulate their own life forces of the body in self-healing (Inozemtsev, V. P., I. I. inform [the, A. G. Nezhdanov. The quantum treatment of cows at metritis and mastitis. Veterinary science. - 2000. - No. 10. - P. 9-12).
The disadvantage of this method of treatment is that the efficacy of laser treatment is to 81.9%.
The purpose of the invention: enhancing the effectiveness of the treatment, suppression of pathogenic microflora of milk, shortening the treatment, and reducing the economic costs of treatment.
This goal is achieved impact on part of the udder of animals with clinical signs of mastitis alternating magnetic field magnetotherapy apparatus Amnp-02 "Sun" in combination with the drug methoxide.
The apparatus Amnp-02 "Sun" is intended to influence for medicinal purposes in different parts of the human body an alternating magnetic field in medical, sanatorium-and-Spa institutions, as well as at home on doctor's advice. Has a low-frequency variables, and automatically changing frequency magnetic field exposure and based on therapeutic effect of changing the cha�tote pulsed magnetic fields. Possesses diverse therapeutic effects: neuro-stimulating, analgesic, anti-edematous, anti-inflammatory, vasoactive, stimulating regeneration in the damaged tissues. Magnetic therapy improves circulation, restores the clotting of blood, stimulates the outflow of secrets from the internal organs, stimulates regenerative and reparative processes in tissues (instructions for use of magnetotherapy apparatus with a low-frequency alternating magnetic field exposure Amnp-02 "Sun". Approved by Order of Roszdravnadzor No. 9642-Ol/09 "01 December 2009).
Methoxide 1% solution has a broad spectrum of antibacterial activity against gram-negative and gram-positive bacteria, Proteus, Pseudomonas aeruginosa and Klebsiella (Bacillus of Friedlander), Salmonella, Staphylococcus, Streptococcus, as well as pathogenic anaerobes. The active substance is dioxidine, which selectively inhibits DNA synthesis in microbial cells without affecting the synthesis of RNA and protein; induces structural changes of the cell wall and nucleotides bacteria, inhibits the activity of extracellular bacterial nucleases and α-toxin. Used for the treatment and prevention of clinical and latent mastitis, as well as for preventive sanitizing treatments udder in n�the beginning of the dry period in cows (instructions for use Metaxalone 1% solution for the prevention and treatment of mastitis in cows).
Our proposed method for the treatment of clinical mastitis cows is as follows: after the evening milking on the part of the udder with signs of clinical mastitis put magnetotherapeutic device Amnp-02 "Sun", the duration of the magnetic field is 10 minutes, magnet therapy course - 4 days. Additionally intracisternal enter methoxide, heated to a temperature of 40°C, at a dose of 20 ml for three days in a row.
Photo 1 shows the fixation magnetotherapy apparatus Amnp-02 "Sun".
Example 1. For the experiment was chosen 60 head of cattle diagnosed with chronic purulent-catarrhal mastitis, which on the basis of pairs of analogues were divided into experimental and control groups (n=30).
Cows first group was treated in a known manner: LTK "Zorka" externally in the area affected shares in mode No. 2, exposure of 2 minutes, morning and evening after milking to 5 days, in combination with the drug Mastie-Forte vnutriarterialno, at a dose of 8 g, once a day after milking until recovery. Cows in the second group were treated with the new proposed method: magnetic radiation by means of the device of "Sun" Amnp-02 topically to the affected area fraction for 10 minutes in the evening after milking for 4 days in complex with mystacidium, heated to 40°, at a dose of 20 ml intracisternal amazed at the proportion of 3 days. RES�the objectives of the effectiveness of these treatment regimens are summarized in table 1.
|Comparative efficacy of combined application of magnetic field and metaxalona for mastitis cows|
|Group||The number of goals||The number of affected shares udder||The number of days of treatment||Recovered||Cured|
As a result of treatment in a new way in the second group have recovered all the cows, and the first where I had used famous�th method of treatment, recovered only 83,3%, which is 16.7% less than in the first group. therapeutic course in the second group was shorter by 1.5 days.
Example 2. In cows the first and second groups (from example 1) was identified and determined by the presence of the species composition of the microflora in udder secretions share with signs of clinical mastitis before treatment and on the last day of treatment (A. D. Tretyakov, 1981. The tests were carried out according to GOST 53430-2009, gostrem 52814-2007, GOST 30347-97, GOST 10444.12-88). The research results secret of the affected udder lobes are presented in table 2.
|The presence of the species composition of the microflora in udder secretions share with signs of purulent-catarrhal mastitis|
|the first group||the second group|
|in the 1-day treatment||on the 4th day of treatment||in the 1-day treatment||on the 5th day of the treatment|
|All investigated samples||65||65||60||60|
|The number of samples with detected mastitis pathogens, including:||62||95,4||0||0||55||91,7||14||23,3|
|Staphylococcus aureus||27||a 43.5||0||0||24||43,6||7||50,0|
|Fungi of the genus Candida||5||8,1||0||0||4||a 7.3||1||7,1|
|Proteus vulgaris||2||3,2||0||0||3||a 5.4||0||0|
|Escherichia coli||8||13,0||0||0||7||a 12.7||2||14,3|
According to the results of bacteriological examination, in the second group of cows on the fourth day of treatment of samples with mastitis pathogens were not detected in comparison with the first group, this suggests that the treatment magnetotherapy apparatus Amnp-02 "Sun" in combination with mystacidium suppression of pathogenic organisms is 100%.
A method for the treatment of clinical mastitis, including the effects of alternating magnetic field on the part of the udder of animals with signs to�imicheskogo mastitis magnetotherapy apparatus Amnp-02 "Sun" after the evening milking for 4 days, the duration of exposure of 10 minutes and an additional intracisternally introduction methoxinine, heated to a temperature of 40°C, at a dose of 20 ml for three consecutive days.
SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.
EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.
3 cl, 6 ex
FIELD: veterinary medicine.
SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.
EFFECT: use of claimed group of inventions increases the efficiency of treatment.
4 cl, 7 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.
6 cl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.
7 cl, 1 ex
SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.
EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.
3 cl, 2 tbl, 1 ex
SUBSTANCE: present invention refers to medicine. The preparation contains the active substance furacilin (nitrofural, 2-[(5-nitro-2-furanyl)methylen]hydrazine carboxamide), the excipient - sodium chloride, a gas-forming mixture, an acidity regulator for reducing pH from 6.5 to 7.5 and a lubricant if needed. The gas-forming mixture consists of an organic acid and sodium hydrocarbonate. According to the method for preparing effervescent tablets of furacilin, furacilin and sodium chloride are milled in a combination; all the ingredients are placed into a mixer, and the prepared mixture is tabletted by direct compression. The antimicrobial therapeutic preparation of furacilin in the form of effervescent tablets is used for septic wounds, bed sores, small skin damages, including scratch marks, abrasions, cuts; infectious-inflammatory oral and throat diseases, including acute tonsillitis, stomatitis, gingivitis and tonsillitis. The effervescent tablets of furacilin are storage-stable for two years and water-soluble at room temperature for 5 minutes.
EFFECT: preparing the antimicrobial therapeutic preparation in the form of the effervescent tablets used for preparing the solution for local and external application.
4 cl, 6 tbl, 3 ex
SUBSTANCE: biologically active additive Laviocard+ is prescribed orally 1 capsule 2 times a day with food for 21 days. That is combined with daily wound irrigations with neutral analyte of anhydrohexitol nucleic acid with leaving a sterile gauze bandage impregnated with neutral analyte of anhydrohexitol nucleic acid in the wound until it is clean. That is followed by daily bandaging with Lavitol cosmetic dihydroquercetin powder applied on the wound surface 1-2 mm thick until the wound is healed.
EFFECT: reduced length of wound healing by stimulating the regeneration processes in tissues.
1 ex, 3 tbl
SUBSTANCE: inorganic clay, represented by sodium-calcium, and/or calcium and/or ferrous forms of montmorillonite, is modified with a water solution of silver nitrate with a concentration 0.16-9.9 wt % in a weight ratio clay:water solution of silver nitrate 1:5. Modification is carried out with mixing from 3 to 7 hours at a temperature in the interval from 10°C to the temperature of boiling. The obtained material is washed with distilled water to pH ≈6-5, until excess of silver nitrate is removed, stood at room temperature and decanted. The material is dried at a temperature of 20-160°C.
EFFECT: obtaining an efficient antibacterial material for traditional and veterinary medicine.
2 tbl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.
EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.
1 tbl, 3 ex
SUBSTANCE: magnetotherapeutic unit contains the magnetic conductor of inductor designed as a stator of an axial asynchronous engine with radially located grooves for three-phase winding over which in the radial direction the boxes for patients are placed with the board from ferromagnetic material in the form of ferromagnetic powder installed over them with a possibility of movement. The board along its radius is divided into sections with filling of each of them ferromagnetic powder, thus magnetic permeability of powder in each subsequent section increases from the external radius of the board to the internal one.
EFFECT: invention allows to smoothen the value of magnetic induction along the length of bodies of patients.
SUBSTANCE: method involves doing therapeutic exercises and pulsed ultrasonic therapy at a pulse length of 10 ms. That is combined with the magnetic stimulation of the shoulder girdle muscles: m. trapezius m. deltoideus, m. supraspinatus, m. infraspinatus on the involved side. That involves the exposure in accordance with a stable technique with using paired pulses of the length of 220±20 mcs at a pulse repetition frequency of 25±5 pulse/min and a pulse-to-pulse spacing of 80 ms for 3 min per one field. The exposure intensity is 70-90% of the maximum magnetic induction amplitude 1,300 mT. The total length of the procedure is 12 minutes. Then 30 minutes later, mud therapy is conducted by applications on the involved shoulder joint. A mud cake temperature makes 38-40 degrees, and the length of the exposure makes 20 minutes. The mud therapy is followed by ultrasonic therapy. The exposure covers the rotator cuff and attachment points of the tendons - m. supraspinatus, m. infraspinatus, m. teres minor on the involved side. The exposure follows a labile technique at an intensity of 0.2-0.4 W/cm2 for 2 minutes per each field at the total length of the procedure of 8 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.
EFFECT: method enables clinical effectiveness by recovering the motor activity of the involved extremity and prolongs the remission, prevents the progression of the biomechanical and neurodystrophic disorders, and formation of neurological complications.
1 ex, 4 tbl, 1 dwg
SUBSTANCE: method involves conducting a standard therapy, exposing to a magnetic field and doing a treadmill workout. The standard therapy involves following a stationary regimen, keeping a standard diet, administering Cytoflavin 10ml in normal saline 150ml, lipoic acid 25mg twice a day and Grandaxin 0.05 3 times a day. The treadmill workout involves as follows. The first workout: first two minutes at 1km/h, from 3rd to 15th minutes at 2km/h, from 16th to 17th minutes at 1km/h, from 18th to 30th minutes at 2km/h, from 31st to 32nd minute at 1km/h. The second work out: first two minutes at 1km/h, from 3rd to 15th minutes at 3km/h, from 16th to 17th minutes at 1km/h, from 18th to 30th minutes at 3km/h, from 31st to 32nd minute at 1km/h. From the 3rd to 10th work out: first two minutes at 3km/h, from 3rd to 30th minutes at 5km/h, from 31st to 32nd minute at 3km/h. The therapeutic course is 10 procedures. The patient is exposed to the magnetic field 30 minutes after the treadmill workout. That involves a transcranial bitemporal magnetic therapy by means of an headband adaptor of AMO-ATOS apparatus. On the first 3 procedures, the exposure is generated at frequency 5 Hz; on the 4-10th procedure - at frequency 10 Hz. The length of exposure is 10 minutes. The therapeutic course is 10 sessions.
EFFECT: method provides activating the cardiovascular functional reserves, reliable blood pressure decrease and stabilisation, body weight reduction, and improved adaptive body capabilities.
SUBSTANCE: method involves a preclinical electroneuromyography (ENMG) of the neuromuscular apparatus of injured and intact lower extremities to measure a muscle response amplitude - an M-response. The findings are recorded. Starting from the second postoperative day, in the course of the drug-induced neuroprotective treatment and therapeutic exercises, the following therapy is additionally performed for 10-15 days. If the injured M-response amplitude is below 4.0 mV, while the respective intact value is more than 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity is performed. If the injured M-response amplitude is more than 4.0 mV, while the respective intact value is below 4.0 mV, the stimulating passive physical treatment covering the intact extremity is performed. If the M-response amplitude of the injured and intact extremities is below 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity and the stimulating passive physical treatment covering the intact extremity are performed. Three and six months following the surgical management, the repeated ENMG of the neuromuscular apparatus of the lower extremities to measure the M-response amplitude. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity three months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity six months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical functional treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed by walking electrical stimulation of the hip and shin.
EFFECT: method reduces the length of treatment and increases its effectiveness with decreasing a percentage of neurological complications by performing the individual complex exposure on the neuromuscular apparatus of the lower extremities taking into account the ENMG findings of the neuromuscular apparatus of the lower extremities.
2 cl, 3 ex
SUBSTANCE: method involves retrobulbar administration of dexamethasone, intramuscular administration of cerebrolysin and proserine, intravenous administration of nootropil. The preparations are introduced for 10 days. Administration further is followed by a percutaneous transcranial pulse magnetic stimulation and an electric stimulation of the optic nerve once a day for 10 days. The magnetic stimulation is performed at the magnetic field strength 2 T, modulation frequency 1 Hz. The exposure covers four points in the projection of the optical nerve sequentially: eyes, temporal region, postaural region, inion - for 5 minutes on each point. The electric stimulation represents the exposure to negative train pulses a frequency of which is equal to a patient's pulse rate at an electrical characteristic not less than 10-15 mC per one session.
EFFECT: method prolongs the remission of optical neuritis in the patients suffering multiple sclerosis.
2 ex, 1 tbl
SUBSTANCE: rehabilitation of children with chronic microbial-inflammatory urinary diseases with the low immune status is ensured by the staged rehabilitation treatment of patients in the stage of complete and partial clinical and laboratory remission. The first stage involves a complex whereat the patient is exposed to ultraviolet short-wave beams according to the standard technique including tonsils, and endonasally according to the standard technique every second day within the 16-21-day therapeutic course. That is followed by a helper stimulation of a chest by means of Helper apparatus with using 19, 20 and 21 sternal point for 3-5 minutes for each within the 7-10-day daily therapeutic course. Therapeutic exercises and phytotherapy are prescribed next with using essences, namely sage, or mint, or aniseed, or eucalypt essences, every second day within the 7-10-day therapeutic course. Thereafter, 3-4 months later at the second stage of rehabilitation, inhalations with immunopotentiating agents, namely 0.5% lysozyme, or sodium nucleinate, or aralia infusion, or ginseng infusion, or eleuterococcus infusion, or aloe extract are prescribed in the form of 10-15 minute daily procedures. The adrenal glands are stimulated with a low-frequency alternating magnetic field generated by Polus-1 stimulator, daily for 10-20 minutes within the therapeutic course of 10-20 procedures. That is followed by the helper stimulation of a thymus by means of Helper apparatus with using 19, 20 and 21 sternal point for 3-5 minutes for each within the 7-10-day therapeutic course. The patient does therapeutic exercises. At the 3rd stage 3-4 months later, the patient is subject to an extremely high frequency electromagnetic exposure covering the middle one-third of the sternum for 5-25 minutes within the therapeutic course of 8-10 procedures, daily or every second day; or the thymus helper stimulation is applied; or a splenin or interferon phonophoresis on the submandibular lymph nodes is alternated with a complex immune preparation on wings of nose with the length of exposure 2-3 minutes within the therapeutic course of 8-10 procedures daily or every second day. The complex certainly includes a halotherapy consisting in 12-25 daily session of the length of 30 minutes, a chest massage and therapeutic exercises. The final 4th stage involves cold water treatment as provided by standard techniques, helper stimulation of the sternum and feet, therapeutic massage, therapeutic exercises, swimming, pine baths or contrast shower. The length and therapeutic course are selected individually for each child.
EFFECT: higher effectiveness of the rehabilitation treatment, namely the recovery of the main disease, reduced intercurrent infections, normalised immunogram ensured by the staged rehabilitation program aiming at the non-invasive targeted effect on the immune system.
SUBSTANCE: method involves a dietary therapy, taking mineral water in an amount of 100-150 ml, 3 times a day and exposure to a physical factor. What is used is the Pevzner's diet No. 5. Karachinskaya chloride-hydrocarbonate sodium gas-free mineral water of total mineralisation up to 3 g/dm3, at a temperature of 38-40°C is taken 30-40 minutes before a meal. The physical factor represents a magnetic laser therapy and an EHF therapy. The contact magnetic laser therapy covers three zones sequentially at a frequency of 5 Hz: an epigastric zone and the right and left upper hypochondria along the midclavicular lines, for 4 minutes for each zone within the course of 10 procedures. The EHF therapy involves combined exposure on two projection zones: in the right hypochondrium and on the sternum generated by a broadband noise emitter at an emission frequency of 40-63 GHz, for 20 minutes, every day within the course of 10 procedures.
EFFECT: method provides more effective rehabilitation treatment following endoscopic cholecystectomy ensured by the early integrated therapeutic exposure.
2 ex, 4 tbl
SUBSTANCE: invention refers to medicine, namely to stimulating metabolic processes experimentally. The patient is exposed to a pulse magnetic field. Thereafter, an inductor coil is applied with its north pole placed on the regions with maximum prominent trophic involvements, a projection of a distal aorta, iliac and femoral arteries. The exposure represents three 7-day courses daily every 5 days. On the first two days of the first course, the exposure length is 7 minutes, the frequency is 5 Hz, the voltage is 600 V, and also for 3 minutes at the frequency of 1 Hz, the voltage of 600 Hz. On the following two days, the voltage increases to 650 V, the exposure length increases by 1 minute at both frequencies. On the following three days of the first course, the voltage increases to 700 V, the exposure length increases by 1 minute at both frequencies. The second course is characterised by the voltage of 700 V, the exposure length increased at both frequencies on the third, fifth, and seventh sessions. The third course is performed daily at the voltage of 700 V at the maximum exposure length of 10 minutes at the frequency of 5 Hz, and of 6 minutes at the frequency of 1 Hz.
EFFECT: method enables repairing the microcirculatory vessels.
2 ex, 1 dwg
SUBSTANCE: invention refers to medicine, namely - to physiotherapy and gynaecology. A method involves the exposure of a projection of ovaries and transcranially in a bitemporal region to magnetic field. The above regions are exposed to magnetic field at frequency 15 Hz for 20 minutes. That is combined with the transcranial electric stimulation at pulse train repetition frequency 77Hz and amplitude 4 V. The therapeutic course is 5-7 days.
EFFECT: method reduces the length of the female ovulatory cycle recovery following an ovarian surgery.
SUBSTANCE: coordination exercises are performed including a complex isotonic-isometric, isometric and isotonic exercises that focus on deep stabilising muscles of the spine. The exercises are performed continuously with small-range motions with regulated respiration: motional expiration, relaxing inhalation from six preparatory positions: sitting on an exercise ball, lying on an exercise ball, lying on one's back, lying on one's side, pronating, standing on all fours using an exercise ball and a rubber band tourniquet with a background relaxation instrumental music. A work out duration is 35-40 minutes; in the afternoon, the patient's lumbosacral region is exposed to an alternating magnetic field in the continuous mode at magnetic field induction 30 mT and length 15 minutes. The procedures are daily; the therapeutic course is 10-12 procedures.
EFFECT: method enables reducing the length of treatment, improving the spinal motor functions and patient's quality of life.
SUBSTANCE: therapeutic device comprises a therapeutic element having a disposable and a reusable portion and comprising a processor connected to a temperature sensor of the heated tissue. The therapeutic element has a place to inject the preparation into the tissue in the pre-set tissue point at the specific moment of time. A processor-controlled heating element is integrated into the therapeutic element or adjoins it; the heat is applied to the tissue in the specified point over the specified period of time: before, during and/or after the therapeutic agent is administered, and the tissue is heated to the pre-set temperature, which is less than the pre-set threshold temperature. Depending on the tissue temperature, the processor stabilises heating at the pre-set temperature. The disposable portion comprises an identification element to indicate whether the portion is in use. An indicator of the therapeutic element is configured to indicate whether the specific injection point is in use.
EFFECT: using the invention enables preventing the re-injection into the same point.
17 cl, 6 dwg